Current Status of Transcatheter Tricuspid Valve Therapies

Romeo, Jared D; Bashline, Michael; Fowler, Jeffrey; Kliner, Dustin; Toma, Catalin; Smith, AJ Conrad; Sultan, Ibrahim; Sanon, Saurabh

doi:10.17925/hi.2022.16.1.49

Cited by 8 publications

(7 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PASCAL Ace implant complements the PASCAL platform and features a smaller spacer that fills the regurgitant orifice, designed to reduce stress on leaflets. 10) Its narrower 6 mm-wide paddle profile allows increased curvature around the spacer for more leaflet surface area capture and a larger neo-coaptation area. The PASCAL Ace implant also allows a staged leaflet capture with independent actuation.…”

Section: Pascalmentioning

confidence: 99%

Transcatheter Tricuspid Valve Intervention: Our Experience and the Current Status in the US

Sugiura,

Assafin,

et al. 2024

Journal of Transcatheter Valve Therapies

View full text Add to dashboard Cite

Severe tricuspid regurgitation (TR) is now widely thought of as a significant contributor to cardiac morbidity and mortality. Neither medical therapy nor conventional surgery is efficacious for most patients. In contrast, with the rapid development of transcatheter tricuspid valve therapies, TR can now be corrected without incurring the risks of conventional surgery, and it is showing promise to improve quality of life and mortality. In this review, we discuss transcatheter tricuspid valve interventions (TTVIs), the current status of clinical trials in the United States, TTVI devices we have used, and our experience.

show abstract

Section: Pascalmentioning

confidence: 99%

Transcatheter Tricuspid Valve Intervention: Our Experience and the Current Status in the US

Sugiura,

Assafin,

et al. 2024

Journal of Transcatheter Valve Therapies

View full text Add to dashboard Cite

show abstract

“…Horizontal right ventricular orientation may be associated with an unfavorable IVC-tricuspid annulus offset angle and may render transfemoral venous approach unsuitable. A transjugular approach can be considered in this situation [21], but may also be limited by unfavorable angulation with current-generation SGCs.…”

Section: Patient Factorsmentioning

confidence: 99%

Which lesions are not amenable to tricuspid clipping?

Bakar,

Fam

2023

Current Opinion in Cardiology

View full text Add to dashboard Cite

Purpose of review Tricuspid transcatheter edge-to-edge repair (T-TEER) has emerged as a well tolerated and effective therapeutic option for many patients with symptomatic severe tricuspid regurgitation at prohibitive surgical risk. However, there remain several important limitations to clip-based technology in the context of other rapidly emerging percutaneous treatment options for tricuspid regurgitation. Recent findings Tricuspid lesions pose unique challenges to treatment with the current toolbox of transcatheter clip-based technologies. This review will explore key issues related to patient factors, anatomical factors, and imaging factors that may render lesions to be unsuitable for treatment with T-TEER. Summary Selection for T-TEER must include a detailed clinical evaluation in the context of a ‘heart team’ approach involving multiple subspecialists, with screening for patient/lesion characteristics that make T-TEER suboptimal with current clip-based technologies. Future directions for research include patient-specific 3D modeling techniques, leaflet grasping techniques, clip deployment strategies, and personalized device sizing to increase the spectrum of lesions that may be treated with T-TEER within the context of other emerging transcatheter treatment options.

show abstract

“…The TriClip device (Abbott, Chicago, IL, USA) is a transcatheter edge-to-edge approximation device which is deployed via a transfemoral delivery system for the percutaneous treatment of tricuspid regurgitation [48]. The initial data from the TriValve registry included 249 patients with severe TR treated with edge-to-edge repair and showed improvements in TR severity (TR <2+ in 72% of patients) and functional status (NYHA class <II in 69% of patients) at one year [19].…”

Section: Edge-to-edge Tricuspid Valve Repairmentioning

confidence: 99%

Structural Interventions in Heart Failure: Mending a Broken Heart

Katzianer

Albert

2023

JCM

View full text Add to dashboard Cite

Advanced heart failure is often accompanied by perturbations in cardiac chamber or valve geometries which result in worsening cardiac function and hemodynamics. Once limited to surgical procedures, recent developments in minimally invasive percutaneous techniques have demonstrated efficacy in patients with both reduced and preserved ejection fraction who are at an elevated surgical risk for perioperative events. This review highlights a subset of the interventions available in clinical practice or in development for the treatment of these valvular and structural alterations.

show abstract

Current Status of Transcatheter Tricuspid Valve Therapies

Cited by 8 publications

References 74 publications

Transcatheter Tricuspid Valve Intervention: Our Experience and the Current Status in the US

Transcatheter Tricuspid Valve Intervention: Our Experience and the Current Status in the US

Which lesions are not amenable to tricuspid clipping?

Structural Interventions in Heart Failure: Mending a Broken Heart

Contact Info

Product

Resources

About